Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
Launched by NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) · Aug 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Screening, Evaluation, and Assessment (SEA) Protocol at the National Institute on Drug Abuse (NIDA) is a research study aimed at better understanding substance use disorders (SUD) and alcohol use disorders (AUD). The goal is to find out why some people use drugs, why some stop, why some can use drugs without becoming addicted, and why others never use drugs at all. This knowledge can help develop better treatments for those struggling with these issues. The study is open to individuals aged 18 and older, whether they currently use substances, have used them in the past, or have never used them.
If you decide to participate, you will come in for a screening visit that may last up to 8 hours, possibly spread over multiple days. During this visit, you will complete various tests, including physical exams, blood and urine tests, mental health evaluations, and questionnaires about your drug use and personal history. It’s important that participants can read, write, and understand English, and are willing to follow the screening procedures. This study is currently recruiting participants, and everyone is welcome, regardless of gender. Your participation could help improve understanding and treatment of substance use disorders.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • This protocol is seeking individuals with current or past SUDs and/or AUD, as well as those who have never had an SUD or AUD. These individuals also may or may not be in treatment for their AUD/SUDs.
- To be eligible to participate in this study, an individual must meet the following criteria:
- • Age 18-99 years old.
- • Proficient ability to read, write, and understand English.
- • Stated willingness to comply with all screening procedures and availability for the duration of the screening period
- • Ability of subject to understand and the willingness to sign a written informed consent document.
- EXCLUSION CRITERIA:
- • Individuals who lack capacity to consent to research participation to this protocol as determined by the Evaluation to Sign Consent (ESC).
About National Institute On Drug Abuse (Nida)
The National Institute on Drug Abuse (NIDA) is a leading federal agency within the U.S. Department of Health and Human Services, dedicated to advancing the understanding of drug abuse and addiction through rigorous scientific research. NIDA's mission encompasses the exploration of the biological, behavioral, and social aspects of substance use disorders, facilitating the development of effective prevention and treatment strategies. By funding and conducting innovative clinical trials, NIDA aims to translate research findings into practical solutions that improve public health and inform policy, ultimately contributing to the reduction of substance-related harm in communities across the nation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Lorenzo Leggio, M.D.
Principal Investigator
National Institute on Drug Abuse (NIDA)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported